ASP Isotopes Inc. Files 8-K for Material Agreement

Ticker: ASPI · Form: 8-K · Filed: Nov 28, 2025 · CIK: 1921865

Sentiment: neutral

Topics: material-agreement, filing

TL;DR

ASP Isotopes Inc. filed an 8-K on Nov 27, 2025, reporting a material definitive agreement. Details to follow.

AI Summary

ASP Isotopes Inc. filed an 8-K on November 28, 2025, reporting an entry into a material definitive agreement and other events. The filing also includes financial statements and exhibits. The company is incorporated in Delaware and its principal executive offices are located in Washington, D.C.

Why It Matters

This 8-K filing indicates a significant development for ASP Isotopes Inc., potentially involving a new contract or partnership that could impact its business operations and financial future.

Risk Assessment

Risk Level: medium — Material definitive agreements can introduce new risks or opportunities, the nature of which is not yet fully disclosed in this initial filing.

Key Players & Entities

FAQ

What is the nature of the material definitive agreement entered into by ASP Isotopes Inc. on November 27, 2025?

The filing indicates an 'Entry into a Material Definitive Agreement' as an item of disclosure, but the specific details of the agreement are not provided in this initial 8-K summary.

What other events are reported in this 8-K filing by ASP Isotopes Inc.?

Besides the material definitive agreement, the filing also reports 'Other Events' and 'Financial Statements and Exhibits'.

When was this 8-K form filed with the SEC?

The 8-K form was filed on November 28, 2025.

Where are the principal executive offices of ASP Isotopes Inc. located?

The principal executive offices of ASP Isotopes Inc. are located at 601 Pennsylvania Avenue NW, South Building, Suite 900, Washington, DC 20004.

What is the Commission File Number for ASP Isotopes Inc.?

The Commission File Number for ASP Isotopes Inc. is 001-41555.

Filing Stats: 1,248 words · 5 min read · ~4 pages · Grade level 12.8 · Accepted 2025-11-28 08:30:39

Key Financial Figures

Filing Documents

01. Entry into a Material Definitive Agreement

Item 1.01. Entry into a Material Definitive Agreement. On November 27, 2025, ASP Isotopes Inc. (the "Company" or "ASP Isotopes") and Renergen Limited ("Renergen"), a South African company listed on the exchange operated by the JSE Limited and the Australian Securities Exchange, entered into a letter agreement to extend the date for the fulfillment of the conditions to the previously announced offer by the Company to acquire 100% of the ordinary shares (excluding treasury shares) of Renergen, pursuant to a scheme of arrangement under South African law pursuant to which Renergen shareholders will receive 0.09196 new ASP Isotopes shares for each Renergen share held on the record date (the "Scheme"). The longstop date, which was originally set at September 30, 2025 and extended by ASP Isotopes to November 28, 2025, has been further extended by mutual agreement to January 30, 2026 in order to allow the parties additional time to satisfy conditions to closing relating to the receipt of the remaining required regulatory approval and certain third party consents. As of November 27, 2025, the implementation of the Scheme remained subject to the approval of the Financial Surveillance Department of the South African Reserve Bank (FinSurv) as provided for in the South African Exchange Control Regulations (in terms of the South African Currency and Exchanges Act, 1933). ASP Isotopes and Renergen continue to pursue a timely approval of the Scheme with FinSurv and certain third parties in order to implement the Scheme as promptly as possible. To date, the Scheme has been approved by the Competition Commission of South Africa, subject to certain conditions, which are acceptable to the Company, and third-party consents have been received from the Industrial Development Corporation of South Africa and the U.S. International Development Finance Corporation. In addition, on November 27, 2025, the Company, ASP Isotopes South Africa Proprietary Limited ("ASPI South Africa") and Rener

Forward-Looking Statements

Forward-Looking Statements This Current Report on Form 8-K contains "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words like "may," "will," "likely," "should," "expect," "anticipate," "future," "plan," "believe," "intend," "goal," "seek," "estimate," "project," "continue," and variations of such words and similar expressions. These forward-looking statements are not guarantees of future performance and involve risks, assumptions, and uncertainties, including, but not limited to, risks related to: (i) the implementation of the Scheme in the anticipated timeframe or at all; (ii) the satisfaction of the Scheme conditions; (iii) the failure to obtain necessary regulatory approvals; (iv) the ability to realize the anticipated benefits of the proposed acquisition of Renergen; (v) the ability to successfully integrate the businesses; (vi) disruption from the proposed acquisition of Renergen making it more difficult to maintain business and operational relationships; (vii) the negative effects of this announcement or the consummation of the proposed acquisition of Renergen on the market price of Renergen's or ASPI's securities; (viii) significant transaction costs and unknown liabilities; (ix) litigation or regulatory actions related to the proposed acquisition of Renergen; and (x) such other factors as are set forth in the periodic reports filed by ASPI with the U.S. Securities and Exchange Commission (the "SEC"), including but not limited to those described under the heading "Risk Factors" in its annual reports on Form 10-K, quarterly reports on Form 10-Q and any other filings made with the SEC from time to time, which are available via the SEC's website at www.sec.gov. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those ind

01. Other Events

Item 8.01. Other Events. On November 27, 2025, ASP Isotopes and Renergen released a joint announcement on the Stock Exchange News Service of the JSE Limited captioned "Scheme of Arrangement – Extension of Outstanding Offer Conditions Fulfilment and Loan Repayment Date," a copy of which is attached as Exhibit 99.1 hereto and is incorporated herein by reference. 2

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. Exhibit No. Description 2.1 Letter Agreement, dated November 27, 2025, by and among ASP Isotopes Inc. and Renergen Limited. 10.1 Letter to the Term Loan Facility Agreement, dated November 27, 2025, by and among ASP Isotopes Inc., ASP Isotopes South Africa Proprietary Limited, as lender, and Renergen Limited, as borrower. 99.1 Joint Announcement released by Renergen and ASP Isotopes Inc. on the Stock Exchange News Service of the JSE Limited on November 27, 2025 regarding Scheme of Arrangement – Extension of Outstanding Offer Conditions Fulfilment and Loan Repayment Date. 104 Cover Page Interactive Date File (embedded within the Inline XBRL document) 3

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ASP ISOTOPES INC. Date: November 28, 2025 By: /s/ Donald G. Ainscow Name: Donald G. Ainscow Title: Executive Vice President, General Counsel and Secretary 4

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing